Testing previous model predictions against new data on human papillomavirus vaccination program outcomes

scientific article

Testing previous model predictions against new data on human papillomavirus vaccination program outcomes is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1009647689
P356DOI10.1186/1756-0500-7-109
P953full work available at URLhttps://bmcresnotes.biomedcentral.com/track/pdf/10.1186/1756-0500-7-109.pdf
P932PMC publication ID3938033
P698PubMed publication ID24568634
P5875ResearchGate publication ID260380563

P50authorMegan SmithQ57071587
Karen CanfellQ70389126
P2860cites workHuman papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach.Q50758405
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.Q51320990
The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.Q51490108
Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.Q51903894
Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd ImmunityQ57089351
Fall in Human Papillomavirus Prevalence Following a National Vaccination ProgramQ61411610
A revision of sexual mixing matrices in models of sexually transmitted infectionQ84677343
Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance dataQ30618714
Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance dataQ33743738
Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination programQ34017208
Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program RegisterQ34051352
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trialQ34342056
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineQ35268615
Modeling preventative strategies against human papillomavirus-related disease in developed countriesQ37198208
The predicted impact of vaccination on human papillomavirus infections in AustraliaQ37219650
Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, AustraliaQ37876979
Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological studyQ44222617
Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidenceQ44504801
P275copyright licenseCreative Commons Attribution 2.0 GenericQ19125117
P6216copyright statuscopyrightedQ50423863
P304page(s)109
P577publication date2014-02-25
P1433published inBMC Research NotesQ15762797
P1476titleTesting previous model predictions against new data on human papillomavirus vaccination program outcomes
P478volume7

Reverse relations

cites work (P2860)
Q38223242Factors impacting HPV vaccination: lessons for health care professionals
Q41114449Factors related to vaccine uptake by young adult women in the catch-up phase of the National HPV Vaccination Program in Australia: Results from an observational study.
Q40470651HPV vaccination: The most pragmatic cervical cancer primary prevention strategy.
Q36251151Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia
Q52745312Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
Q49644195Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia
Q38380092The next steps in cervical screening
Q40569845Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries

Search more.